2. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

pancreatic islet cells

" in MedChemExpress (MCE) Product Catalog:

58

阻害剤およびアゴニスト

2

蛍光色素

8

生化学アッセイ試薬

11

ペプチド

2

阻害性抗体

4

天然物

1

組換えタンパク質

6

同位体標識化合物

2

抗体

8

オリゴヌクレオチド

Targets Recommended:
製品番号 製品名 Target 研究分野 構造式
  • HY-13749
    Sitagliptin
    Maximum Cited Publications
    30 Publications Verification

    MK-0431

    		 Dipeptidyl Peptidase GLP Receptor Endogenous Metabolite PKA ERK Metabolic Disease
    Sitagliptin (MK-0431) is an orally active and highly selective DPP4 inhibitor with an IC50 value of 19 nM. Sitagliptin blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin can be used for the study of 1-type and 2-type diabetes .
    Sitagliptin
  • HY-N0058
    4,5-Dicaffeoylquinic acid
    10+ Cited Publications

    Isochlorogenic acid C

    		 HBV Endogenous Metabolite Apoptosis Glycosidase Infection
    4,5-Dicaffeoylquinic acid (Isochlorogenic acid C) is an antioxidant, can be isolated from Gynura divaricata and Laggera alata. 4,5-Dicaffeoylquinic acid reduces islet cell apoptosis and improves pancreatic function in type 2 diabetic mice, and has obvious inhibitory activities against yeast α-glucosidase. 4,5-Dicaffeoylquinic acid inhibits prostate cancer cells through cell cycle arrest. 4,5-Dicaffeoylquinic acid also has anti-apoptotic, anti-injury and anti-hepatitis B virus effects .
    4,5-Dicaffeoylquinic acid
  • HY-13749A
    Sitagliptin phosphate
    Maximum Cited Publications
    30 Publications Verification

    MK-0431 phosphate

    		 Dipeptidyl Peptidase GLP Receptor Endogenous Metabolite PKA ERK Metabolic Disease
    Sitagliptin (MK-0431) phosphate is an orally active and highly selective DPP4 inhibitor with an IC50 value of 19 nM. Sitagliptin phosphate blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin phosphate can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin phosphate shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin phosphate can be used for the study of 1-type and 2-type diabetes .
    Sitagliptin phosphate
  • HY-B0481
    Miglitol
    2 Publications Verification

    BAY1099; BAY-m1099

    		 Glycosidase AMPK Reactive Oxygen Species (ROS) Metabolic Disease
    Miglitol (BAY-m1099) is an orally active antidiabetic compound that inhibits the breakdown of glycoconjugates into glucose. Miglitol inhibits glycoside hydrolase enzymes called α-glucosidases. Miglitol inhibits oxidative stress-induced apoptosis and mitochondrial ROS over-production in endothelial cells by enhancement of AMP-activated protein kinase. Dietary supplementation with Miglitol from pre-onset stage in OLETF rats delays the onset and development of diabetes and preserves the insulin secretory function of pancreatic islets .
    Miglitol
  • HY-13749B
    Sitagliptin phosphate monohydrate
    Maximum Cited Publications
    30 Publications Verification

    MK-0431 phosphate monohydrate

    		 Dipeptidyl Peptidase GLP Receptor Endogenous Metabolite PKA ERK Metabolic Disease
    Sitagliptin (MK-0431) phosphate monohydrate is an orally active and highly selective DPP4 inhibitor with an IC50 value of 19 nM. Sitagliptin phosphate monohydrate blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin phosphate monohydrate can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin phosphate monohydrate shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin phosphate monohydrate can be used for the study of 1-type and 2-type diabetes .
    Sitagliptin phosphate monohydrate
  • HY-P10735
    GIP (mouse)

    Gastric inhibitory polypeptide(mouse); GIP(1-42) (mouse)

    		 Lipase Apoptosis Metabolic Disease
    GIP (Gastric inhibitory polypeptide) (mouse) is a gastrointestinal hormone that is secreted by the intestinal K cells, and also expressed in and secreted from pancreatic islets. GIP (mouse) promotes insulin secretion from pancreatic β cells via the G-protein-coupled GIP receptor (GIPR). GIP (mouse) promotes pancreatic β cell proliferation and inhibits apoptosis. GIP (mouse) also exerts direct lipogenic effects on adipose tissue .
    GIP (mouse)
  • HY-101020
    Picolinamide

    2-Picolinamide

    		 PARP Metabolic Disease
    Picolinamide (2-Picolinamide) is an inhibitor of Poly(ADP-ribose) synthetase of nuclei from rat pancreatic islet cells .
    Picolinamide
  • HY-13981
    Ligandrol
    2 Publications Verification

    LGD-4033

    		 Androgen Receptor Apoptosis Insulin Receptor Caspase Metabolic Disease Endocrinology
    Ligandrol is an orally active, selective androgen receptor (AR) agonist. Ligandrol enhances protein synthesis, inhibits muscle breakdown and oxidative stress, improves muscle cell viability and bone tissue microstructure, and reduces Cisplatin (HY-17394)-induced muscle toxicity and apoptosis. Ligandrol promotes muscle growth, protects bone structure, and has anti-diabetic, anti-apoptotic and antioxidant effects. Ligandrol can antagonize Streptozotocin (HY-13753) damage to pancreatic islets and improve the symptoms of type 2 diabetes .
    Ligandrol
  • HY-B0254
    Glipizide
    2 Publications Verification

    CP 28720; K 4024

    		 Potassium Channel Metabolic Disease Cancer
    Glipizide (CP 2872; K 4024)?a potent, orally active and sulfonylurea class anti-diabetic agent and can be used for type 2?diabetes mellitus research but not type 1. Glipizide acts by partially blocking ATP-sensitive potassium?(KATP) channels among β cells of pancreatic islets of Langerhans .
    Glipizide
  • HY-P1745
    InsB (9-23)

    Insulin B chain (9-23)

    		 MHC Insulin Receptor IFNAR Inflammation/Immunology
    InsB (9-23) (Insulin B chain (9-23)) is an HLA-DQ8-restricted insulin B-chain peptide composed of amino acid residues 9-23. InsB (9-23) serves as a major MHC II class-restricted antigen. InsB (9-23) supports the recognition and activation of T cells, stimulates the secretion of IFN-γ and cytokines, and induces cross-reactive immune responses. InsB (9-23)-specific CD4 T cells can initiate diabetes . InsB (9-23) can be used in research related to type 1 diabetes and autoimmune diabetes .
    InsB (9-23)
  • HY-12462
    WS3

    		Keap1-Nrf2 Inflammation/Immunology
    WS3 is a novel proliferative molecule that promotes pancreatic β cell proliferation in rodent and human primary islets. WS3 can be used for the research of type 1 diabetes .
    WS3
  • HY-W145482
    3-O-Methyl-D-glucopyranose

    		Drug Isomer Metabolic Disease
    3-O-Methyl-D-glucopyranose is a non-metabolizable glucose analog. 3-O-Methyl-D-glucopyranose exerts a protective effect against alloxan-induced damage to rat pancreatic islet β cells. 3-O-Methyl-D-glucopyranose can be used in diabetes research .
    3-O-Methyl-D-glucopyranose
  • HY-120565
    WB403

    		G protein-coupled Bile Acid Receptor 1 Metabolic Disease
    WB403 is an orally active TGR5 activator with an EC50 of 5.5 μM against human TGR5. WB403 activates TGR5 to stimulate downstream signaling pathways, promote GLP-1 secretion, improve glucose tolerance in mice with type 2 diabetes, and reduce levels of fasting blood glucose, postprandial blood glucose and HbA1c. WB403 increases pancreatic β-cell mass and restores the distribution of α-cells and β-cells in islets. WB403 is applicable to the research of type 2 diabetes .
    WB403
  • HY-P990254
    Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173)

    		CXCR Inflammation/Immunology Cancer
    Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) is an anti-mouse CXCR3/CD183 IgG monoclonal antibody. Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) weakens the immune response by reducing the infiltration of CD4 + and CD8 + T cells. Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) significantly prolongs the survival time of heart or islet transplants in mice. Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) can be used for researches on immunology and cancer such as pancreatic cancer .
    Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173)
  • HY-132184
    5,6-Epoxyeicosatrienoic acid

    5,6-EET; (±)5,6-EpETrE

    		 Adrenergic Receptor Calcium Channel Endocrinology
    5,6-Epoxyeicosatrienoic acid (5,6-EET; (±)5,6-EpETrE) is a fully racemic version of the enantiomeric forms biosynthesized from arachidonic acid by cytochrome P450 enzymes. In solution, 5,6-Epoxyeicosatrienoic acid degrades into 5,6-DiHET and 5,6-δ-lactone, which can be converted to 5,6-DiHET and quantified by GC-MS. In neuroendocrine cells, such as the anterior pituitary and pancreatic islets, 5,6-Epoxyeicosatrienoic acid has been implicated in the mobilization of calcium and hormone secretion. 5,6-Epoxyeicosatrienoic acid is an inhibitor of T-type voltage-gated calcium channels (Cav3) that inhibits isoforms Cav3.1, Cav3.2 (IC50=0.54 μM), and Cav3. and decreases nifedipine-resistant phenylephrine-induced vasoconstriction in isolated mouse mesenteric arteries via Cav3.2 blockade when used at a concentration of 3 μM. In addition, it is a substrate of COX-1 and COX-2.
    5,6-Epoxyeicosatrienoic acid
  • HY-W110793
    Dithizone

    Diphenylthiocarbazone

    		 Biochemical Assay Reagents Metabolic Disease
    Dithizone can be toxic to pancreatic islet cells and cause experimental diabetes. Dithizone can be used for in vitro in vivo staining of transplanted islets and cytoplasmic granules of bone marrow cells. Dithizone can be used as a chelating agent and colorimetric indicator for the detection and extraction of various heavy metals, including lead and mercury, in analytical and biochemical applications. Dithizone forms stable colored complexes with metal ions and can be quantitatively analyzed by methods such as spectrophotometry .
    Dithizone
  • HY-W017387
    Sodium α-ketoisocaproate
    1 Publications Verification

    Sodium 4-methyl-2-oxopentanoate; 2-Ketoisocaproic acid sodium salt

    		 Branched Chain Amino Acid Transaminase (BCAT) Potassium Channel Na+/Ca2+ Exchanger Metabolic Disease
    Sodium α-ketoisocaproate (Sodium 4-methyl-2-oxopentanoate) is an insulin secretagogue. Sodium α-ketoisocaproate undergoes transamination catalyzed by BCAT and BCATm to produce α-ketoglutarate and leucine; it also binds to the SUR1 site to inhibit KATP channel activity, but does not directly affect the Kir6.2 subunit. Sodium α-ketoisocaproate regulates Ca 2+ influx. Sodium α-ketoisocaproate exerts insulinotropic activity in pancreatic islets and intact mouse pancreata with sufficient BCATm expression. Sodium α-ketoisocaproate can be used in research related to type 2 diabetes .
    Sodium α-ketoisocaproate
  • HY-13749AS
    Sitagliptin-d4 phosphate

    MK-0431-d4 phosphate

    		 Dipeptidyl Peptidase GLP Receptor Endogenous Metabolite PKA ERK Metabolic Disease
    Sitagliptin-d4 phosphate (MK-0431-d4) is the deuterium labeled Sitagliptin phosphate (HY-13749A). Sitagliptin phosphate is an orally active and highly selective DPP4 inhibitor with an IC50 value of 19 nM. Sitagliptin phosphate blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin phosphate can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin phosphate shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin phosphate can be used for the study of 1-type and 2-type diabetes.
    Sitagliptin-d4 phosphate
  • HY-P2612
    WP9QY

    		TNF Receptor RANKL/RANK Apoptosis Inflammation/Immunology
    WP9QY is an inhibitor targeting TNFα and RANKL, which blocks the TNFα-TNFR1 interaction and inhibits TNFα-mediated apoptosis, cytotoxicity and bone destruction. WP9QY inhibits osteoclastogenesis and promotes osteoblast differentiation, induces chondrocyte proliferation and glycosaminoglycan production, and synergizes with TGF-β3 to promote chondrogenesis. WP9QY effectively repairs full-thickness articular cartilage defects in rabbits via intra-articular injection, and inhibits methylmercury-induced reduction of NeuN-positive cells in mouse brain slices. WP9QY can be applied to the research of diseases related to methylmercury-induced neuronal death, cartilage injury, osteoarthritis and bone loss .
    WP9QY
  • HY-P10341
    ZP3022

    		GCGR Metabolic Disease
    ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin that has the ability to sustainably improve glycemic control. Additionally, ZP3022 can effectively increase β-cell mass, promote β-cell proliferation, and enhance the function of pancreatic islets. ZP3022 can be used in anti-diabetic research .
    ZP3022
  • HY-B0254S
    Glipizide-d11

    		Isotope-Labeled Compounds Potassium Channel Metabolic Disease
    Glipizide-d11 is the deuterium labeled Glipizide. Glipizide (CP 2872; K 4024)?a potent, orally active and sulfonylurea class anti-diabetic agent and can be used for type 2?diabetes mellitus research but not type 1. Glipizide acts by partially blocking ATP-sensitive potassium?(KATP) channels among β cells of pancreatic islets of Langerhans .
    Glipizide-d11
  • HY-B0254R
    Glipizide (Standard)

    CP 28720 (Standard); K 4024 (Standard)

    		 Reference Standards Potassium Channel Metabolic Disease
    Glipizide (Standard) is the analytical standard of Glipizide. This product is intended for research and analytical applications. Glipizide (CP 2872; K 4024) a potent, orally active and sulfonylurea class anti-diabetic agent and can be used for type 2 diabetes mellitus research but not type 1. Glipizide acts by partially blocking ATP-sensitive potassium (KATP) channels among β cells of pancreatic islets of Langerhans .
    Glipizide (Standard)
  • HY-13749S1
    Sitagliptin-d4 hydrochloride

    MK-0431-d4 hydrochloride

    		 Isotope-Labeled Compounds Dipeptidyl Peptidase GLP Receptor Endogenous Metabolite PKA ERK Metabolic Disease
    Sitagliptin-d4 hydrochloride is the deuterium labeled Sitagliptin hydrochloride (HY-13749E). Sitagliptin hydrochloride is an orally active and highly selective DPP4 inhibitor with an IC50 value of 19 nM. Sitagliptin hydrochloride blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin hydrochloride can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin hydrochloride shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin hydrochloride can be used for the study of 1-type and 2-type diabetes.
    Sitagliptin-d4 hydrochloride
  • HY-N0058R
    4,5-Dicaffeoylquinic acid (Standard)

    Isochlorogenic acid C (Standard)

    		 Reference Standards HBV Endogenous Metabolite Apoptosis Glycosidase Infection
    4,5-Dicaffeoylquinic acid (Standard) is the analytical standard of 4,5-Dicaffeoylquinic acid. This product is intended for research and analytical applications. 4,5-Dicaffeoylquinic acid (Isochlorogenic acid C) is an antioxidant, can be isolated from Gynura divaricata and Laggera alata. 4,5-Dicaffeoylquinic acid reduces islet cell apoptosis and improves pancreatic function in type 2 diabetic mice, and has obvious inhibitory activities against yeast α-glucosidase. 4,5-Dicaffeoylquinic acid inhibits prostate cancer cells through cell cycle arrest. 4,5-Dicaffeoylquinic acid also has anti-apoptotic, anti-injury and anti-hepatitis B virus effects .
    4,5-Dicaffeoylquinic acid (Standard)
  • HY-176745
    SW016789

    		VDAC Metabolic Disease Endocrinology
    SW016789 is a hypersecretion-inducer targeting VDAC1. SW016789 can induce insulin hypersecretion and Ca 2+ influx in β-cells directly. SW016789 induces a transient endoplasmic reticulum stress response (ER stress), but does not cause beta cell death. SW016789 has reversible and non-apoptotic characteristics. SW016789 can be used for the study of Diabetes mellitus type 2 (T2DM) β-cell dysfunction .
    SW016789
  • HY-13749E
    Sitagliptin hydrochloride

    MK-0431 hydrochloride

    		 Dipeptidyl Peptidase GLP Receptor Endogenous Metabolite PKA ERK Metabolic Disease
    Sitagliptin (MK-0431) hydrochloride is an orally active and highly selective DPP4 inhibitor with an IC50 value of 19 nM. Sitagliptin hydrochloride blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin hydrochloride can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin hydrochloride shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin hydrochloride can be used for the study of 1-type and 2-type diabetes .
    Sitagliptin hydrochloride
  • HY-13967
    AMG 837
    3 Publications Verification

    		 Free Fatty Acid Receptor Bacterial Infection Metabolic Disease
    AMG 837 is an orally active, selective GPR40/FFA1 agonist with an EC50 of 1.5 nM against human GPR40. AMG 837 stimulates insulin secretion in a glucose-dependent manner, and effectively improves glycemic control in both normal and diabetic rodent models . AMG 837 binds to the BacA protein and impairs the survival and replication of Brucella. AMG 837 can be used in research related to type 2 diabetes and brucellosis .
    AMG 837
  • HY-P1871A
    Amylin (IAPP), feline TFA

    		Amylin Receptor Metabolic Disease
    Amylin (IAPP), feline TFA is a 37-amino acid polypeptide from feline. Amylin (IAPP), feline TFA is one of the major secretory products of β-cells of the pancreatic islets. Amylin (IAPP), feline TFA is a regulatory peptide, which inhibits insulin and glucagon secretion .
    Amylin (IAPP), feline TFA
  • HY-120287
    L-054522

    		Somatostatin Receptor Endocrinology
    L-054522 is an agonist for somatostatin receptor subtype 2 with Kd of 0.01 nM. L-054522 inhibits growth hormone release from rat primary pituitary cell (IC50=0.05 nM) and glucagon and insulin release from isolated mouse pancreatic islet cell (IC50=0.05 nM and 12 nM) .
    L-054522
  • HY-174557
    Human PAX6 mRNA

    		mRNA Metabolic Disease
    Human PAX6 mRNA encodes the human paired box 6 (PAX6) protein, a member of the paired box (PAX) family. PAX6 may play an important role in the development of the eye, nose, central nervous system and pancreas. It is also required for the differentiation of pancreatic islet alpha cells.
    Human PAX6 mRNA
  • HY-13749R
    Sitagliptin (Standard)

    MK-0431 (Standard)

    		 Reference Standards Dipeptidyl Peptidase GLP Receptor Endogenous Metabolite PKA ERK Metabolic Disease
    Sitagliptin (Standard) is the analytical standard of Sitagliptin (HY-13749). This product is intended for research and analytical applications. Sitagliptin is an orally active and highly selective DPP4 inhibitor with an IC50 value of 19 nM. Sitagliptin blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin can be used for the study of 1-type and 2-type diabetes.
    Sitagliptin (Standard)
  • HY-101020R
    Picolinamide (Standard)

    2-Picolinamide (Standard)

    		 Reference Standards PARP Metabolic Disease
    Picolinamide (Standard) is the analytical standard of Picolinamide. This product is intended for research and analytical applications. Picolinamide (2-Picolinamide) is an inhibitor of Poly(ADP-ribose) synthetase of nuclei from rat pancreatic islet cells .
    Picolinamide (Standard)
  • HY-P1871
    Amylin (IAPP), feline

    		Amylin Receptor Metabolic Disease
    Amylin (IAPP), feline is a 37-amino acid polypeptide from feline. Amylin (IAPP), feline is one of the major secretory products of β-cells of the pancreatic islets. Amylin (IAPP), feline is a regulatory peptide, which inhibits insulin and glucagon secretion .
    Amylin (IAPP), feline
  • HY-174559
    Human PAX4 mRNA

    		mRNA Metabolic Disease
    Human PAX4 mRNA encodes the human paired box 4 (PAX4) protein, a member of the paired box (PAX) family. PAX4 is involved in pancreatic islet development and mouse studies have demonstrated a role for this gene in differentiation of insulin-producing beta cells.
    Human PAX4 mRNA
  • HY-147207C
    Phospholipid-PEG5000-Biotin

    		Liposome Others
    Phospholipid-PEG5000-Biotin is a phospholipid PEG derivative, can be used for modify liposome and cells surface, and pancreatic islets for cell transplantation. Phospholipid is a class of lipid containing a hydrophilic “head” and two hydrophobic “tails”; PEG is a hydrophilic and water-soluble polymer with low toxicity; Biotin is an enzyme co-factor, can be used for labeling protein .
    Phospholipid-PEG5000-Biotin
  • HY-147207B
    Phospholipid-PEG3400-Biotin

    		Liposome Others
    Phospholipid-PEG3400-Biotin is a phospholipid PEG derivative that has a biotin and a phospholipid bridged by a linear PEG linker. Phospholipid-PEG3400-Biotin can interact with avidinylated antibodies. Phospholipid-PEG3400-Biotin can be used to modify liposome and cells surface, and pancreatic islets for cell transplantation .
    Phospholipid-PEG3400-Biotin
  • HY-147207E
    Phospholipid-PEG20000-Biotin

    		Liposome Others
    Phospholipid-PEG20000-Biotin is a phospholipid PEG derivative that has a biotin and a phospholipid bridged by a linear PEG linker. Phospholipid-PEG20000-Biotin can interact with avidinylated antibodies. Phospholipid-PEG20000-Biotin can be used to modify liposome and cells surface, and pancreatic islets for cell transplantation .
    Phospholipid-PEG20000-Biotin
  • HY-147207
    Phospholipid-PEG1000-Biotin

    		Liposome Others
    Phospholipid-PEG1000-Biotin is a phospholipid PEG derivative that has a biotin and a phospholipid bridged by a linear PEG linker. Phospholipid-PEG1000-Biotin can interact with avidinylated antibodies. Phospholipid-PEG1000-Biotin can be used to modify liposome and cells surface, and pancreatic islets for cell transplantation .
    Phospholipid-PEG1000-Biotin
  • HY-147207A
    Phospholipid-PEG2000-Biotin

    		Liposome Others
    Phospholipid-PEG2000-Biotin is a Biotin labeled phospholipid PEG derivative, can be used for modify liposome and cells surface, and pancreatic islets for cell transplantation. Phospholipid is a class of lipid containing a hydrophilic "head" and two hydrophobic "tails" ; PEG is a hydrophilic and water-soluble polymer with low toxicity; Biotin is an enzyme co-factor, can be used for labeling protein .
    Phospholipid-PEG2000-Biotin
  • HY-164684
    Dichlorobenzamil

    3',4'-Dichlorobenzamil; L-594881

    		 Calcium Channel Sodium Channel Na+/Ca2+ Exchanger Others
    Dichlorobenzamil (3',4'-Dichlorobenzamil; L-594881) is an effective Na/Ca exchange inhibitor. Dichlorobenzamil significantly inhibits 45Ca uptake mediated by reverse Na/Ca exchange in pancreatic islet cells (IC50 = 18 μM). Dichlorobenzamil can also block K + channels and voltage-sensitive Ca 2+ channels .
    Dichlorobenzamil
  • HY-P3608
    [Des-His1,Glu9] Glucagon

    		GCGR Metabolic Disease
    [Des-His1,Glu9] Glucagon is a potent glucagon receptor system peptide antagonist. [Des-His1,Glu9] Glucagon enhances the glucose-stimulated release of insulin from pancreatic islet cells. [Des-His1,Glu9] Glucagon can be used to research diabetes .
    [Des-His1,Glu9] Glucagon
  • HY-P1544
    Cerebellin

    		Endogenous Metabolite Adenylate Cyclase PKA Calcium Channel Neurological Disease Metabolic Disease
    Cerebellin is a neuromodulatory hexadecapeptide that serves as a marker for Purkinje cell maturation. Cerebellin stimulates norepinephrine release via the adenylate cyclase/PKA-dependent signaling pathway. Cerebellin reduces insulin secretion from pancreatic islets under high-glucose conditions. Cerebellin also regulates synaptic structure formation and controls catecholamine secretion in peripheral tissues. Cerebellin can be used in neurological research .
    Cerebellin
  • HY-W145482S1
    3-O-Methyl-D-glucopyranose-13C6

    		Biochemical Assay Reagents Isotope-Labeled Compounds Others
    3-O-Methyl-D-glucopyranose- 13C6 is 13C-labeled 3-O-Methyl-D-glucopyranose (HY-W145482). 3-O-Methyl-D-glucopyranose is a non-metabolizable glucose analog. 3-O-Methyl-D-glucopyranose exerts a protective effect against alloxan-induced damage to rat pancreatic islet β cells. 3-O-Methyl-D-glucopyranose can be used in diabetes research .
    3-O-Methyl-D-glucopyranose-13C6
  • HY-113513
    5-HEPE

    		Others Cancer
    5(S)-HEPE is an active metabolite of eicosapentaenoic acid. It is formed from EPA by 5-lipoxygenase (5-LO). 5(S)-HEPE is an agonist of G protein-coupled receptor 119 (GPR119). It increases cAMP accumulation in CHO-K1 cells expressing human GPR119 when used at a concentration of 10 μM. 5(S)-HEPE increases glucose-induced insulin secretion from MING6 insulinoma pancreatic islets and glucagon-like peptide 1 (GLP-1) secretion from HuTu 80 adenocarcinoma cells when used at a concentration of 10 μM. Serum levels of 5(S)-HEPE are elevated in patients with hyperlipidemia.
    5-HEPE
  • HY-13749AR
    Sitagliptin phosphate (Standard)

    MK-0431 phosphate (Standard)

    		 Reference Standards Dipeptidyl Peptidase GLP Receptor Endogenous Metabolite PKA ERK Metabolic Disease
    Sitagliptin (MK-0431) phosphate (Standard) is the analytical standard of Sitagliptin phosphate (HY-13749A). This product is intended for research and analytical applications. Sitagliptin phosphate is an orally active and highly selective DPP4 inhibitor with an IC50 value of 19 nM. Sitagliptin phosphate blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin phosphate can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin phosphate shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin phosphate can be used for the study of 1-type and 2-type diabetes.
    Sitagliptin phosphate (Standard)
  • HY-13749S2
    Sitagliptin-d4

    MK-0431-d4

    		 Isotope-Labeled Compounds Dipeptidyl Peptidase GLP Receptor Endogenous Metabolite PKA ERK Metabolic Disease
    Sitagliptin-d4 (MK-0431-d4) is deuterium labeled Sitagliptin (HY-13749). Sitagliptin is an orally active and highly selective DPP4 inhibitor with an IC50 value of 19 nM. Sitagliptin blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin can be used for the study of 1-type and 2-type diabetes.
    Sitagliptin-d4
  • HY-13749S3
    Sitagliptin-d6

    MK-0431-d6

    		 Isotope-Labeled Compounds Dipeptidyl Peptidase GLP Receptor Endogenous Metabolite PKA ERK Metabolic Disease
    Sitagliptin-d6 (MK-0431-d6) is deuterium labeled Sitagliptin (HY-13749). Sitagliptin is an orally active and highly selective DPP4 inhibitor with an IC50 value of 19 nM. Sitagliptin blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin can be used for the study of 1-type and 2-type diabetes.
    Sitagliptin-d6
  • HY-13749BR
    Sitagliptin phosphate monohydrate (Standard)

    MK-0431 phosphate monohydrate (Standard)

    		 Reference Standards Dipeptidyl Peptidase GLP Receptor Endogenous Metabolite PKA ERK Metabolic Disease
    Sitagliptin (MK-0431) phosphate monohydrate (Standard) is the analytical standard of Sitagliptin phosphate monohydrate (HY-13749B). This product is intended for research and analytical applications. Sitagliptin phosphate monohydrate is an orally active and highly selective DPP4 inhibitor with an IC50 value of 19 nM. Sitagliptin phosphate monohydrate blocks the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) by competing inhibition mechanism (Kᵢ = 1 nM), thereby increasing the level of active incretin. Sitagliptin phosphate monohydrate can also directly stimulate the secretion of GLP-1 by intestinal L cells by activating the cAMP/PKA and ERK1/2 pathways, and this effect is independent of DPP-4. Sitagliptin phosphate monohydrate shows protective effects on pancreatic islet grafts in 1-type diabetes models. Sitagliptin phosphate monohydrate can be used for the study of 1-type and 2-type diabetes.
    Sitagliptin phosphate monohydrate (Standard)
  • HY-D3174
    PiF

    		Fluorescent Dye Metabolic Disease Inflammation/Immunology
    PiF is a fluorescent probe with high specificity for pancreatic β-cells (Ex/Em = 535 nm/565 nm), and its fluorescence signal increases significantly with elevated insulin concentrations in in vitro experiments. PiF enables visualization of rat and human islets transplanted via the portal vein in mouse livers with low liver background signals. The fluorine atom of PiF can be replaced by radioactive 18F to prepare a PET tracer. PiF can be used for research on type 1 diabetes .
    PiF
  • HY-D3173
    TP-α

    TPG-456

    		 Fluorescent Dye GCGR Metabolic Disease
    TP-α is a glucagon-selective two-photon fluorescent probe with a Kd of 65 μM. TP-α directly interacts with glucagon to produce significant fluorescence enhancement. TP-α selectively stains viable glucagon-secreting α cells in pancreatic islets, enabling visualization of their localization, distribution and availability. TP-α is applicable to diabetes research .
    TP-α

オンラインお問い合わせ

入力情報は安全に管理されます. ※ 必須入力項目.

タイトル

  

国或いは地域 *

お名前 *

 

組纖名 *

デパートメント *

     

メールアドレス *

 

製品名 *

製品番号

  

カスタマ需要量 *

電話番号 *

     

必ず会社名を記載ください。個人への返信は行いません。

備考

バルクお問い合わせ

Inquiry Information

製品名:
製品番号:
数量:
MCE 日本正規代理店: